Torrent Pharmaceuticals Intrinsic Value
Torrent Pharmaceuticals (TORNTPHARM) median intrinsic value is ₹1361.34 from 9 valuation models (range ₹993–₹2850), vs current price ₹4537.80 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Browse TORNTPHARM financial statements for revenue, profit, balance sheet and cash flow data.
TORNTPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Torrent Pharmaceuticals intrinsic value across 9 models vs current price ₹4537.80 — upside/downside and value range per method. Also explore Torrent Pharmaceuticals stock price data download to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1361.34 | ₹1089.07 - ₹1633.61 | -70.0% | EPS: ₹46.04, Sector P/E: 22x |
| Book Value Method | asset | ₹992.78 | ₹893.50 - ₹1092.06 | -78.1% | Book Value/Share: ₹496.39, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1946.04 | ₹1751.44 - ₹2140.64 | -57.1% | Revenue/Share: ₹973.02, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2849.70 | ₹2564.73 - ₹3134.67 | -37.2% | EBITDA: ₹4816.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1815.12 | ₹1452.10 - ₹2178.14 | -60.0% | CF Growth: 6.6%, Discount: 15% |
| PEG Ratio Method | growth | ₹1361.34 | ₹1225.21 - ₹1497.47 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1361.34 | ₹1225.21 - ₹1497.47 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2268.90 | ₹2042.01 - ₹2495.79 | -50.0% | ROE: 17.4%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1361.34 | ₹1225.21 - ₹1497.47 | -70.0% | EPS: ₹46.04, BVPS: ₹496.39 |
TORNTPHARM Intrinsic Value vs Market Price — All Valuation Models
Torrent Pharmaceuticals fair value range ₹993–₹2850 vs current market price ₹4537.80 across 9 valuation models. For current market price and key ratios, visit Torrent Pharmaceuticals share price today.
TORNTPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Torrent Pharmaceuticals median intrinsic value ₹1361.34, current price ₹4537.80 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of TORNTPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Torrent Pharmaceuticals (TORNTPHARM) is ₹1361.34 (median value). With the current market price of ₹4537.80, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹992.78 to ₹2849.70, indicating ₹992.78 - ₹2849.70.
Is TORNTPHARM undervalued or overvalued?
Based on our multi-method analysis, Torrent Pharmaceuticals (TORNTPHARM) appears to be trading above calculated value by approximately 70.0%.
TORNTPHARM Financial Health — Key Ratios vs Industry Benchmarks
Torrent Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.51 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 17.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.37x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
TORNTPHARM Cash Flow Quality — Operating & Free Cash Flow
Torrent Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹2,585 Cr | ₹2,311 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹3,266 Cr | ₹3,186 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹2,368 Cr | ₹1,201 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1,803 Cr | ₹1,705 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹2,005 Cr | ₹1,783 Cr | Positive Free Cash Flow | 8/10 |